Oncoscience 
Welcome,         Profile    Billing    Logout  
 1 Product   63 Diseases  1 Product   144 Trials   754 News 
154 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
ChiCTR1900021853: A real world study for nimotuzumab combined with radiotherapy and chemotherapy in the treatment of patients with advanced and recurrent oral and oropharyngeal squamous cell carcinoma

Recruiting
4
320
 
nimotuzumab+chemotherapy+radiotherapy ;nimotuzumab+radiotherapy ;chemotherapy+radiotherapy ;radiotherapy
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 'Special funds for tumor targeting research' granted by NationalInstitute of Hospital Administration, NIHA
advanced or recurrent oral and oropharyngeal squamous cell carcinoma
 
 
NCT06879691: A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
4
171
RoW
Nimotuzumab, H-R3, cis-platinum, cisplatin, IMRT combine with cisplatin concurrent chemotherapy, painkiller
Biotech Pharmaceutical Co., Ltd., Baotou Cancer Hospital
Head and Neck Cancer
04/25
04/25
ChiCTR2000039917: Clinical efficacy of nimotuzumab combined with EGFR TKIs and EGFR TKIs in the treatment of meningeal metastasis of lung cancer

Recruiting
4
30
 
尼妥珠单抗联合EGFR-TKIs 尼妥珠单抗联合EGFR-TKIs 16/2000 Nimotuzumab combined with EGFR-TKIs ;EGFR-TKIs alone
The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, self-raised
Leptomeningeal metastasis
 
 
ChiCTR2100042563: A study of nituzumab combined with chemoradiotherapy in the treatment of advanced lacal laryngopharyngeal carcinoma

Recruiting
4
30
 
Nituzumab concurrent chemoradiotherapy
Harbin Medical University Affiliated Tumor Hospital; Harbin Medical University Affiliated Tumor Hospital, Enterprise financing
Laryngeal pharyngeal squamous cell carcinomas
 
 
ChiCTR2100044100: The effect of nimotuzumab combined with analgesics in the treatment of locally advanced head and neck squamous cell carcinoma

Recruiting
4
98
 
Pain medication plus concurrent chemoradiotherapy ;Nimotuzumab + pain medication + concurrent chemoradiotherapy
Department of Head and Neck Surgery, Baotou Cancer Hospital; Department of Head and Neck Surgery, Enterprise subsidy
Squamous cell carcinoma of head and neck
 
 
ChiCTR2100053476: A single-arm clinical study of nitrozumab in combination with concurrent radiotherapy for unresectable locally advanced squamous oesophageal cancer

Not yet recruiting
4
30
 
Nimotuzumab, Albumin paclitaxel, Cisplatin, radiotherapy
Cangzhou Central Hospital; Cangzhou Central Hospital, No
Esophageal neoplams
 
 
ChiCTR2100047135: A single arm, single center clinical trial of salvage surgery combined with Nimotuzumab and Camrelizumab adjuvant therapy for local recurrence of nasopharyngeal carcinoma

Recruiting
4
43
 
Operation combined with Nimotuzumab and Camrelizumab treatment
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Self-raised
nasopharyngeal carcinoma
 
 
ChiCTR2200066975: A prospective and cohort study of nimotuzumab at different gradient doses combined with concurrent chemoradiotherapy in the treatment of stage II.B-III.C of locally advanced cervical cancer

Not yet recruiting
4
88
 
Chemoradiotherapy ;Chemoradiotherapy in combination with nimotuzumab 100 mg weekly ;Chemoradiotherapy in combination with nimotuzumab 200 mg weekly ;Chemoradiotherapy in combination with nimotuzumab 400 mg weekly
Chengdu Fifth People's Hospital; Chengdu Fifth People's Hospital, Self-funded
Cervical cancer
 
 
ChiCTR2100053094: Single-arm, Single-center Clinical Study of Salvage Surgery Combined with Camrelizumab and Nimotuzumab in Patients with Locally Recurrent Nasopharyngeal Carcinoma after Re-irradiation

Recruiting
4
10
 
Postoperative adjuvant Camrelizumab and Nimotuzumab
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Self-raised
Nasopharyngeal carcinoma
 
 
ChiCTR2300078481: Nimotuzumab based comprehensive treatment regimen for pancreatic cancer Prospective real-world study

Recruiting
4
112
 
NA; NA; NA
Anhui Cancer Hospital; Anhui Cancer Hospital, Patients pay for themselves
Pancreatic cancer
 
 
ChiCTR2200067130: Surgery and adjuvant radiotherapy/chemoradiotherapy combined with or without nimotuzumab for locally advanced oral cavity carcinoma: a non-randomized controlled trial

Recruiting
4
100
 
if there is no high risk factor, postoperative adjuvant radiotherapy was performed, and Nitozumab 200 mg QW (6 cycles) was synchronized; If there are high risk factors, concurrent postoperative adjuvant radiotherapy with cisplatin and nituzumab 200 mg QW (6 cycles). After radiotherapy, during the maintenance phase, ;postoperative adjuvant radiotherapy without high risk factors; If there are high risk factors, postoperative adjuvant radiotherapy should be concurrent with cisplatin.
Peking University Hospital of Stomatology; Peking University Hospital of Stomatology, China zhongguancun Precision Medicine science and technology foundation
oral cavity carcinoma
 
 
2015-002185-23: The study is designed for patients diagnosed with a brain tumor (diffuse intrinsic pontine glioma) aged from 2 to 21 years old. Lo studio è pensato per pazienti affetti da un tumore cerebrale (glioma diffuso intrinseco del ponte) che abbiano età compresa tra 2 e 21 anni.

Not yet recruiting
3
79
Europe
Vinorelbina, Cimaher, [vinorelbina], [Cimaher], Solution for injection, Solution for infusion, NAVELBINE - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONE 1 ML, CIMAher
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", donazioni modali
diffuse intrinsic pontine glioma glioma diffuso intrinseco del ponte, children and adolescent affected by malignant glioma of the brain stem bambini e adolescenti di età superiore a 2 anni affetti da glioma maligno del tronco encefalico, Diseases [C] - Cancer [C04]
 
 
NCT06781073: Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Completed
3
118
RoW
Nimotuzumab, h-R3, Paclitaxel, Paclitaxel Injection, Cisplatin, Cisplatin for Injection, Placebo, Nimotuzumab Placebo
Biotech Pharmaceutical Co., Ltd.
Cervical Squamous Cell Carcinoma, Persistent
11/24
12/24
ChiCTR-IPR-15006277: Nimotuzumab (Taixinsheng) in combination with gemcitabine contrast to placebo in combination with gemcitabine K-RAS wild-type treatment of locally advanced or metastatic pancreatic cancer in a prospective, Randomized, controlled, double-blind, multi-center clinical study

Recruiting
3
276
 
nimotuzumab+Gemcitabine ;Placebo+Gemcitabine
81th Hospital of PLA; biotech pharmaceutical co., ltd, biotech pharmaceutical co.,ltd
pancreatic cancer
 
 
TheraCIM1: Stydy of DE-766 in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Recruiting
3
420
Japan
TheraCIM (nimotuzumab)
Daiichi Sankyo
NSCLC
 
 
NCT04456322: Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
3
381
RoW
RT plus Nimotuzumab, RT plus Cisplatin, Cisplatin
Sun Yat-sen University
Nasopharyngeal Carcinoma
05/24
05/27
NCT04532229: Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Recruiting
3
48
RoW
Nimotuzumab+CRT(concurrent IMRT and TMZ), h-R3
Biotech Pharmaceutical Co., Ltd.
Diffuse Intrinsic Pontine Glioma
10/23
12/23
NCT00957086: Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Active, not recruiting
3
710
RoW
Nimotuzumab, Placebo
National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore, Innogene Kalbiotech Pte. Ltd
Carcinoma, Squamous Cell of Head and Neck
01/25
01/25
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Recruiting
3
384
RoW
Nimotuzumab, Cisplatin
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
02/24
02/24
NOTABLE-308, NCT06343116: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not yet recruiting
3
420
NA
Nimotuzumab injection, Taixinsheng, Placebo, Trifluridine/tipiracil
Biotech Pharmaceutical Co., Ltd.
Refractory Metastatic Colorectal Cancer
04/27
04/27
NCT06333821: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruiting
3
460
NA
Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab, placebo
Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
04/30
04/30
NCT06561763: TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting
3
416
NA
Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
Sun Yat-sen University
High Risk Locally Advanced Nasopharyngeal Carcinoma
08/28
08/31
NCT05772208: Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting
3
459
RoW
Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT
Fudan University
Nasopharyngeal Carcinoma
01/25
01/28
ChiCTR2400084464: Pancreatectomy with combined targeted therapy and neoadjuvant chemotherapy in locally advanced pancreatic cancer

Recruiting
3
20
 
Ninituzumab + Gemcitabine plus albumin-bound purpurinol+Radical resection
West China Hospital , Sichuan University; West China Hospital , Sichuan University, Biotech Pharmaceuticals Co., Ltd
Pancreatic Ductal Adenocarcinoma
 
 
NCT06026878: GNT Induction Treatment in Locally Advanced NPC

Recruiting
3
228
RoW
gemcitabine,nimotuzumab, toripalimab, GNT, gemcitabine, cisplatin, GP
Air Force Military Medical University, China
Nasopharyngeal Carcinoma
09/25
09/27
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting
3
2000
RoW
Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer
12/25
12/25
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting
3
2000
RoW
Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect
12/25
12/25
NOTABLE-307, NCT05978050: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting
3
354
RoW
nimotuzumab plus paclitaxel, Combined with chemotherapy, placebo plus paclitaxel, chemotherapy alone
Biotech Pharmaceutical Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
03/26
IST-Nim-PC 45, NCT06409429: Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Not yet recruiting
2/3
146
RoW
Nimotuzumab, h-R3, GX, Placebo
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
05/27
05/27
ACTRN12610000560099: A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
88
 
YM BioSciences Inc., YM BioSciences Inc.
Non-Small Cell Lung Cancer with brain metastases
 
 
ACTRN12610000571077: A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination with External Radiotherapy in Stage IIB, III and IV Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
128
 
YM BioSciences Inc., YM BioSciences Inc.
Non-Small Cell Lung Cancer (NSCLC)
 
 
ChiCTR-ONC-12002130: Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma

Completed
2
39
 
cisplatin+5-Fu+nimotuzumab
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sponsored by Biotech Pharmaceuticals Co.Ltd.
Metastatic Nasopharyngeal Carcinoma
 
 
ChiCTR-IIR-16007712: Nimotuzumab (Taixinsheng) combined with radiotherapy and chemotherapy for protecting the laryngeal function of locally advanced hypopharyngeal and laryngeal cancer patients: a multi-center, single-blind, randomized, controlled, phase II study

Recruiting
2
100
 
nimotuzumab (200mg) combine with Radiotherapy and Cisplatin ;nimotuzumab (200mg) combine with Radiotherapy and Docetaxel
People's Liberation Army General Hospital; People's Liberation Army General Hospital, biotech pharmaceutical co.,ltd
Hypopharyngeal cancer, laryngeal cancer
 
 
GASTO 1010, NCT02428764: Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Withdrawn
2
37
RoW
Nimotuzumab, Gemcitabine, Gemzar, Carboplatin, CBP, Surgery
Sun Yat-sen University
Lung Cancer
10/25
10/27
ChiCTR-OIC-16008201: Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy follow by cisplatin synchronous intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: a multicenter, prospective phase II study

Recruiting
2
60
 
Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy
The fourth affiliated hospital of Guangxi Medical University; The fourth affiliated hospital of Guangxi Medical University, Key specialist funds
Locally advanced nasopharyngeal carcinoma
 
 
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recruiting
2
67
RoW
Nimotuzumab, Radiation
Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital
Recurrent Nasopharyngeal Carcinoma
04/20
11/22
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Recruiting
2
47
RoW
Nimotuzumab, Taixinsheng, VMAT
Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
05/20
05/22
NCT03708822: Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
2
48
RoW
Docetaxel and Cisplatin and Nimotuzumab
Sun Yat-sen University
Nasopharyngeal Carcinoma
07/22
06/24
CC11, NCT06771596: Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Active, not recruiting
2
43
RoW
Nimotuzumab Injection, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Uterine Cervical Neoplasms
07/25
09/25
NCT04136600: EGFR Monoclonal Antibody for Advanced Gastric Cancer

Recruiting
2
100
RoW
EGFR antibody and Chemotherapy, Chemotherapy
Shanghai Changzheng Hospital
Gastric Cancer, Cetuximab, Nimotuzumab
08/21
12/21
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Completed
2
55
RoW
Radiotherapy, Nimotuzumab, S-1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm
12/22
06/23
Carpp-1, NCT04882462: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Not yet recruiting
2
100
NA
Nimotuzumab, Sintilimab, Chemotherapy drug
The First Affiliated Hospital of Soochow University, Biotech Pharmaceutical Co., Ltd., Cinda Biopharmaceutical (Suzhou) Co., Ltd.
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
11/21
12/22
NCT04367909: A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Recruiting
2
68
RoW
Nimotuzumab, Docetaxel, Carboplatin
Xin-Hua Xu
Oral Squamous Cell Carcinoma
12/21
12/22
NCT04833205: Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Recruiting
2
30
RoW
Nimotuzumab, EGFR-TKI
Hui Bu
Leptomeningeal Metastasis, Lung Cancer
04/22
04/23
NCT06404840: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Recruiting
2
30
RoW
nimotuzumab, AG chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
03/25
05/26
DIPG, NCT03620032: Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

Active, not recruiting
2
54
Europe
Nimotuzumab, humanized therapeutic monoclonal antibody, Vinorelbine, Chemotherapy, Radiotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University of Roma La Sapienza, Johannes Gutenberg University Mainz, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Wuerzburg University Hospital
Diffuse Intrinsic Pontine Glioma
11/22
11/24
NCT04223024: Concurrent Chemoradiotherapy with Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Active, not recruiting
2
246
RoW
CCRT+Nimotuzumab, Nimotuzumab, CCRT alone
Sun Yat-sen University
Nasopharyngeal Carcinoma
08/24
12/26
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
45
RoW
Nimotuzumab + SHR-1210
The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
12/22
09/23
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
NCT06455072: Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Recruiting
2
37
RoW
Nituzumab, monoclonal antibody, Serplulimab, Immune checkpoint inhibitors
Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province
Cervical Cancer
01/25
01/25
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Recruiting
2
53
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Recruiting
2
55
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
IST-Nim-ESCC-18, NCT06718205: Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
112
RoW
Nimotuzumab, Sintilimab, Paclitaxel-albumin, Cisplatin
The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer
09/25
09/25
NCT06405685: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Recruiting
2
30
RoW
Nimotuzumab, h-R3, AG
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
10/25
10/25
ChiCTR2000035678: Concurrent nimotuzumab with intensity modulated radiotherapy for locoregionally advanced aged nasopharyngeal carcinoma

Not yet recruiting
2
95
 
Concurrent nimotuzumab with intensity modulated radiotherapy
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, none
nasopharyngeal carcinoma
 
 
ChiCTR2100049181: Nimotuzumab plus chemotherapy for unresectable locally advanced or metastatic pancreatic cancer and biliary tract cancer: an open-label, prospective, phase II basket trial

Not yet recruiting
2
16
 
None
Peking University International Hospital; Peking University International Hospital, self-funded
pancreatic cancer and biliary tract cancer
 
 
NCT06413017: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Recruiting
2
30
RoW
Nimotuzumab, h-R3, ICIs(Immune checkpoint inhibitors), PD-1 or PD-L1
Tianjin Medical University Cancer Institute and Hospital
HCC
07/25
12/25
NCT05508347: Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Recruiting
2
170
RoW
Nituzumab/placebo, Nituzumab injection (taixinsheng)
Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Carcinoma
10/25
10/27
NCT06389760: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Recruiting
2
57
RoW
Nimotuzumab, Taixinsheng, mFOLFIRINOX, GX
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Cancer
09/26
09/26
GCR-05, NCT05606263: Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer

Recruiting
2
55
RoW
Caldonirimab and Nimotuzumab
Health Science Center of Xi'an Jiaotong University
Cervical Cancer
11/23
11/25
NCT04664244: Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Recruiting
2
43
RoW
Combination of nimotuzumab and radiotherapy
Lei Li
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab, Objective Response Rate, Progression-free Survival, Overall Survival
12/23
12/23
ChiCTR2100041780: Nimotuzumab combined with PD-1 Sintilizumab in the second-line treatment of advanced esophageal squamous cell carcinoma: a single-arm, open phase II clinical study

Recruiting
2
42
 
Nimotuzumab combined with sintilizumab
The Sixth Medical Center of PLA General Hospital; The Sixth Medical Center of PLA General Hospital, BIOTECH PHARMA
Esophageal Carcioma
 
 
ChiCTR2100051133: A single-center, single-arm, phase II clinical study of the efficacy and safety of nimotuzumab combined with sintilimab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma

Not yet recruiting
2
41
 
Nimotuzumab combined with Sintilimab
The Fifth Affiliated Hospital of Guangzhou Medical University; The Fifth Affiliated Hospital of Guangzhou Medical University, Enterprise subsidy
squamous cell carcinoma of the head and neck
 
 
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
22
RoW
Anti-PD1 antibody, nimotuzumab and capecitabine
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
02/26
08/26
NCT06988956: Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting
2
95
RoW
Nimotuzumab, Nim, Tegafur, S-1, radiotherapy
The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma
04/27
04/27
ChiCTR2200058765: A Phase II study of the safety and efficacy of sintilimab in combination with chemotherapy and Nimotuzumab induction therapy, Nimotuzumab synchronous radiotherapy (IMRT), followed by six months of maintenance therapy with sintilimab in advanced nasopharyngeal carcinoma

Recruiting
2
30
 
sintilimab combined nimotuzumab
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Innovent Biological Inc (Suzhou)
nasopharyngeal carcinoma
 
 
NCT06429904: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Active, not recruiting
2
31
RoW
Nimotuzumab+ NALIRIFOX
Peking Union Medical College Hospital
Locally Advanced Pancreatic Cancer
05/27
05/27
NCT06414577: Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Active, not recruiting
2
38
RoW
Irinotecan Liposomal combined With Nituzumab
XIANG YANQUN
Nasopharyngeal Cancer
03/25
03/25
ChiCTR2200060564: Nimotuzumab combined with neoadjuvant chemotherapy (TPF) in the treatment of resectable locally advanced head and neck squamous cell carcinoma

Not yet recruiting
2
55
 
Nimotuzumab combined with chemotherapy (PF protocol)
Xijing Hospital of the Air Force Military Medical University; Xijing Hospital of the Air Force Military Medical University, Enterprise funding
Head and neck squamous cell carcinoma
 
 
NCT05351762: Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Not yet recruiting
2
55
NA
Nimotuzumab Combined With Neoadjuvant Chemotherapy, Albumin Paclitaxel, Nedaplatin, Teggio
Xijing Hospital
Head and Neck Squamous Cell Carcinoma
05/24
07/24
Nim-PC-28, NCT06422156: SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Not yet recruiting
2
73
NA
Stereotactic body radiation, SBRT, Nimotuzumab, h-R3, mono-chemotherapy, chemotherapy
Peking University Third Hospital, Biotech Pharmaceutical Co., Ltd.
Advanced Pancreatic Cancer
06/26
06/26
NCT06490341: GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

Not yet recruiting
2
20
NA
GP Regimen, Nimotuzumab, Sintilimab, no other invention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Nasopharyngeal Carcinoma
07/26
07/27
NCT06509009: Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
2
30
NA
Nimotuzumab, no other invention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma by AJCC V8 Stage
05/26
05/27
NCT05803915: Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Not yet recruiting
2
57
RoW
Toripalimab, JS001
Peking Union Medical College Hospital
Oral Squamous Cell Carcinoma
09/24
03/26
ChiCTR2100043937: A single-arm, open phase II clinical study to evaluate the efficacy and safety of Nimotuzumab Injection combined with concurrent chemoradiotherapy in elderly patients with locally advanced inoperable esophageal squamous cell carcinoma

Recruiting
2
23
 
Nimotuzumab, Tegafur Gimer and radiotherapy
Affiliated Hospital of Nantong University; Level of the institution：, None
esophageal squamous carcinoma
 
 
NCT06039891: Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Not yet recruiting
2
55
NA
Nimotuzumab、Tislelizumab, Nimotuzumab, Tislelizumab plus radiotherapy
Peking Union Medical College Hospital
Cervical Cancer
10/24
10/27
NCT06676722: SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

Recruiting
2
20
RoW
SBRT combined with Nimotuzumab followed by Tislelizumab
The First Affiliated Hospital of Xiamen University
Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
12/26
12/27
NCT06722911: Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Recruiting
2
57
RoW
Nimotuzumab, AG
Zhejiang Provincial People's Hospital
Pancreatic Cancer Resectable
09/28
09/28
NOTABLE-309, NCT06781086: Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting
2
156
RoW
Nimotuzumab, AG regimen, Placebo
Biotech Pharmaceutical Co., Ltd., Peking University Cancer Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer, Adult
12/28
12/28
NCT06770452: HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Not yet recruiting
2
32
RoW
HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel
Zhejiang University
Metastatic Pancreatic Carcinoma
02/27
02/28
ChiCTR2300068872: Clinical study of rre-combined nimouzumab for reversing drug resistance in hepatocellular carcinoma after failure of treatment of 1-L lenalutinib-containing regimen

Recruiting
2
37
 
nimotuzumab，400mg，D1,8,15,28d/cycle
The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Hospital), Self-financing
hepatocelluar carcinoma
 
 
NCT06938503: AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Not yet recruiting
2
48
NA
AG regimen, Nimotuzumab
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Adult
04/28
04/28
NCT05316480: Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Not yet recruiting
2
42
RoW
Nimotuzumab
Fudan University
Pancreatic Neuroendocrine Neoplasm
04/25
12/26
NCT06912711: TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Not yet recruiting
2
70
RoW
Toripalimab, Nimotuzumab, surgery
Sun Yat-sen University
Nasopharyngeal Carcinoma
04/29
04/29
ChiCTR2000034375: TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Not yet recruiting
2
29
 
TIP (paclitaxel + ifosfamide + cisplatin)+Nimotuzumab+Triprilimab
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Self-financing
Penile Caner
 
 
NCT06048913: Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

Completed
2
56
RoW
Nimotuzumab, taixinsheng, S-1, chemotherapy, Concurrent radiation therapy, Chemoradiotherapy
The First Affiliated Hospital with Nanjing Medical University
Esophageal Carcinoma
01/25
01/25
NCT05024019: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Not yet recruiting
2
95
RoW
Nimotuzumab
Eye & ENT Hospital of Fudan University
Head and Neck Squamous Cell Carcinoma
08/25
08/25
NCT05355168: Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Completed
2
35
RoW
neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
Anhui Provincial Hospital
Toxicity, Drug
12/23
03/24
ChiCTR2100054151: Clinical study of neoadjuvant chemoradiation combined with Nimotuzumab and Camrelizumab in the treatment of resectable/potentially resectable locally advanced esophageal cancer

Not yet recruiting
2
57
 
Camrelizumab + Nimotuzumab + Carboplatin + Albumin Paclitaxel + radiotherapy + surgery
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Jiangsu Hengrui Pharmaceutical Co., Ltd.; Baitai Biological Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma
 
 
ChiCTR2000041139: An open-label, single-arm phase II clinical study of nimotuzumab concurrently with induction chemotherapy and sequential nimotuzumab combined with radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Recruiting
2
76
 
Nimotuzumab plus induction chemotherapy,sequential nimotuzumab plus radiotherapy or nimotuzumab combined with concurrent chemoradiotherapy
The second affiliated hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, Self-financing
Nasopharyngeal carcinoma
 
 
ChiCTR2200064587: Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy in patients with advanced head and neck cancer: A phase II singel arm trial

Not yet recruiting
2
48
 
Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy
Xijing Hospital; Xijing Hospital, clinical trials project of the air force medical university
head neck cancer
 
 
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study

Recruiting
2
26
China
The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1,000 mg/m2), Cisplatin, intravenous infusion, day 1 (80 mg/m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650 mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study.
Dongguan People's Hospital; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd.
nasopharyngeal carcinoma
 
 
ChiCTR2300072843: Prospective study of nituzumab combined with gemcitabine and albumin paclitaxel in first-line treatment of advanced pancreatic cancer

Recruiting
2
31
 
nituzumab combined with gemcitabine and albumin paclitaxel
Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Own in-hospital support
pancreatic cancer
 
 
ChiCTR2400084660: A prospective, single arm study of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer

Not yet recruiting
2
31
 
1. Nimotuzumab: Dosage:*400 mg, administered intravenously once a week (QW); or 1600 mg divided into three doses, administered intravenously on days 1, 8, and 15 (600 mg + 600 mg + 400 mg), with a 28-day treatment cycle. Preparation:Dissolve 8 vials (400 mg) of nimotuzumab injection in 250 ml of normal saline, or dissolve 12 vials (600 mg) of nimotuzumab injection in 380 ml of normal saline. The infusion time should be at least 60 minutes.2. Chemotherapy: Regimen:NALIRIFOX Components:Liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2 administered intravenously, followed by 5-FU 2400 mg/m2 continuous infusion over 46 hours. Schedule:Administered on days 1 and 15, with a 28-day cycle.
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Biotech Pharmaceutical Co., Ltd.
pancreatic cancer
 
 
ChiCTR2200063496: A prospective, single arm, phase II study of neoadjuvant treatment of resectable head and neck tumors with nituzumab combined with epimumab

Not yet recruiting
2
51
 
Nytuzumab was combined with ipilimumab ;Nytuzumab was combined with ipilimumab
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Clinical medicine research project of Tianjin Medical University General Hospital
Head and neck squamous cell carcinoma
 
 
ChiCTR2400084470: A Single-Arm, Multi-Center, Prospective Phase II Clinical Study on the neoadjuvant Tislelizumab-Nimotuzumab-GP followed by concurrent Tislelizumab-Nimotuzumab-IMRT and maintenance Tislelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma at High Risk

Recruiting
2
31
 
Neoadjuvant Tislelizumab-Nivolumab-GP followed by concurrent Tislelizumab-Nivolumab-IMRT and maintenance Tislelizumab
Fujian Cancer Hospital; Fujian Cancer Hospital, none
Locally Advanced Nasopharyngeal Carcinoma
 
 
ChiCTR2500099125: A phase II clinical study on neoadjuvant therapy of esophageal squamous cell carcinoma with tislelizumab combined with nimotuzumab and chemotherapy

Not yet recruiting
2
40
 
Tislelizumab injection Nimotuzumab injection paclitaxel for injection (albumin-bound) Cisplatin injection
Shanxi Cancer Hospital; Shanxi Cancer Hospital, self-funding
esophageal squamous cell carcinoma
 
 
ChiCTR2200057917: Phase II clinical study of nituzumab combined with first-line chemotherapy in the treatment of advanced esophageal squamous cell carcinom

Not yet recruiting
2
60
 
Nituzumab combined with chemotherapy
Cancer Hospital Affiliated to Harbin Medical University; Cancer Hospital Affiliated to Harbin Medical University, enterprise sponsor
esophagus cancer
 
 
ChiCTR2500103027: A prospective phase II study of stratified treatment of initially resectable locally advanced HNSCC based on pathological response after neoadjuvant chemo-immunotherapy

Recruiting
2
30
 
Patientsreceived tislelizumab chemotherapy for 2-3 cycles for neoadjuvant treatment . Patients who achieved MPR after surgery received tislelizumab; patients who did not achieve MPR received standard adjuvant radiotherapy combined with nimotuzumab, followed by tislelizumab.
The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, The First Affiliated Hospital of China Medical University
Head and neck squamous cell carcinoma
 
 
ChiCTR2500101420: A single-arm, single-center, open, prospective phase II clinical study of camrelizumab combined with nimotuzumab and first-line chemoradiotherapy for the treatment of recurrent and metastatic cervical cancer

Not yet recruiting
2
42
 
Camrelizumab + Nimotuzumab + CCRT
Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital, None
Recurrent and metastatic cervical cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
ChiCTR1900021853: A real world study for nimotuzumab combined with radiotherapy and chemotherapy in the treatment of patients with advanced and recurrent oral and oropharyngeal squamous cell carcinoma

Recruiting
4
320
 
nimotuzumab+chemotherapy+radiotherapy ;nimotuzumab+radiotherapy ;chemotherapy+radiotherapy ;radiotherapy
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 'Special funds for tumor targeting research' granted by NationalInstitute of Hospital Administration, NIHA
advanced or recurrent oral and oropharyngeal squamous cell carcinoma
 
 
NCT06879691: A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
4
171
RoW
Nimotuzumab, H-R3, cis-platinum, cisplatin, IMRT combine with cisplatin concurrent chemotherapy, painkiller
Biotech Pharmaceutical Co., Ltd., Baotou Cancer Hospital
Head and Neck Cancer
04/25
04/25
ChiCTR2000039917: Clinical efficacy of nimotuzumab combined with EGFR TKIs and EGFR TKIs in the treatment of meningeal metastasis of lung cancer

Recruiting
4
30
 
尼妥珠单抗联合EGFR-TKIs 尼妥珠单抗联合EGFR-TKIs 16/2000 Nimotuzumab combined with EGFR-TKIs ;EGFR-TKIs alone
The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, self-raised
Leptomeningeal metastasis
 
 
ChiCTR2100042563: A study of nituzumab combined with chemoradiotherapy in the treatment of advanced lacal laryngopharyngeal carcinoma

Recruiting
4
30
 
Nituzumab concurrent chemoradiotherapy
Harbin Medical University Affiliated Tumor Hospital; Harbin Medical University Affiliated Tumor Hospital, Enterprise financing
Laryngeal pharyngeal squamous cell carcinomas
 
 
ChiCTR2100044100: The effect of nimotuzumab combined with analgesics in the treatment of locally advanced head and neck squamous cell carcinoma

Recruiting
4
98
 
Pain medication plus concurrent chemoradiotherapy ;Nimotuzumab + pain medication + concurrent chemoradiotherapy
Department of Head and Neck Surgery, Baotou Cancer Hospital; Department of Head and Neck Surgery, Enterprise subsidy
Squamous cell carcinoma of head and neck
 
 
ChiCTR2100053476: A single-arm clinical study of nitrozumab in combination with concurrent radiotherapy for unresectable locally advanced squamous oesophageal cancer

Not yet recruiting
4
30
 
Nimotuzumab, Albumin paclitaxel, Cisplatin, radiotherapy
Cangzhou Central Hospital; Cangzhou Central Hospital, No
Esophageal neoplams
 
 
ChiCTR2100047135: A single arm, single center clinical trial of salvage surgery combined with Nimotuzumab and Camrelizumab adjuvant therapy for local recurrence of nasopharyngeal carcinoma

Recruiting
4
43
 
Operation combined with Nimotuzumab and Camrelizumab treatment
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Self-raised
nasopharyngeal carcinoma
 
 
ChiCTR2200066975: A prospective and cohort study of nimotuzumab at different gradient doses combined with concurrent chemoradiotherapy in the treatment of stage II.B-III.C of locally advanced cervical cancer

Not yet recruiting
4
88
 
Chemoradiotherapy ;Chemoradiotherapy in combination with nimotuzumab 100 mg weekly ;Chemoradiotherapy in combination with nimotuzumab 200 mg weekly ;Chemoradiotherapy in combination with nimotuzumab 400 mg weekly
Chengdu Fifth People's Hospital; Chengdu Fifth People's Hospital, Self-funded
Cervical cancer
 
 
ChiCTR2100053094: Single-arm, Single-center Clinical Study of Salvage Surgery Combined with Camrelizumab and Nimotuzumab in Patients with Locally Recurrent Nasopharyngeal Carcinoma after Re-irradiation

Recruiting
4
10
 
Postoperative adjuvant Camrelizumab and Nimotuzumab
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Self-raised
Nasopharyngeal carcinoma
 
 
ChiCTR2300078481: Nimotuzumab based comprehensive treatment regimen for pancreatic cancer Prospective real-world study

Recruiting
4
112
 
NA; NA; NA
Anhui Cancer Hospital; Anhui Cancer Hospital, Patients pay for themselves
Pancreatic cancer
 
 
ChiCTR2200067130: Surgery and adjuvant radiotherapy/chemoradiotherapy combined with or without nimotuzumab for locally advanced oral cavity carcinoma: a non-randomized controlled trial

Recruiting
4
100
 
if there is no high risk factor, postoperative adjuvant radiotherapy was performed, and Nitozumab 200 mg QW (6 cycles) was synchronized; If there are high risk factors, concurrent postoperative adjuvant radiotherapy with cisplatin and nituzumab 200 mg QW (6 cycles). After radiotherapy, during the maintenance phase, ;postoperative adjuvant radiotherapy without high risk factors; If there are high risk factors, postoperative adjuvant radiotherapy should be concurrent with cisplatin.
Peking University Hospital of Stomatology; Peking University Hospital of Stomatology, China zhongguancun Precision Medicine science and technology foundation
oral cavity carcinoma
 
 
2015-002185-23: The study is designed for patients diagnosed with a brain tumor (diffuse intrinsic pontine glioma) aged from 2 to 21 years old. Lo studio è pensato per pazienti affetti da un tumore cerebrale (glioma diffuso intrinseco del ponte) che abbiano età compresa tra 2 e 21 anni.

Not yet recruiting
3
79
Europe
Vinorelbina, Cimaher, [vinorelbina], [Cimaher], Solution for injection, Solution for infusion, NAVELBINE - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONE 1 ML, CIMAher
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", donazioni modali
diffuse intrinsic pontine glioma glioma diffuso intrinseco del ponte, children and adolescent affected by malignant glioma of the brain stem bambini e adolescenti di età superiore a 2 anni affetti da glioma maligno del tronco encefalico, Diseases [C] - Cancer [C04]
 
 
NCT06781073: Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Completed
3
118
RoW
Nimotuzumab, h-R3, Paclitaxel, Paclitaxel Injection, Cisplatin, Cisplatin for Injection, Placebo, Nimotuzumab Placebo
Biotech Pharmaceutical Co., Ltd.
Cervical Squamous Cell Carcinoma, Persistent
11/24
12/24
ChiCTR-IPR-15006277: Nimotuzumab (Taixinsheng) in combination with gemcitabine contrast to placebo in combination with gemcitabine K-RAS wild-type treatment of locally advanced or metastatic pancreatic cancer in a prospective, Randomized, controlled, double-blind, multi-center clinical study

Recruiting
3
276
 
nimotuzumab+Gemcitabine ;Placebo+Gemcitabine
81th Hospital of PLA; biotech pharmaceutical co., ltd, biotech pharmaceutical co.,ltd
pancreatic cancer
 
 
TheraCIM1: Stydy of DE-766 in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Recruiting
3
420
Japan
TheraCIM (nimotuzumab)
Daiichi Sankyo
NSCLC
 
 
NCT04456322: Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
3
381
RoW
RT plus Nimotuzumab, RT plus Cisplatin, Cisplatin
Sun Yat-sen University
Nasopharyngeal Carcinoma
05/24
05/27
NCT04532229: Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Recruiting
3
48
RoW
Nimotuzumab+CRT(concurrent IMRT and TMZ), h-R3
Biotech Pharmaceutical Co., Ltd.
Diffuse Intrinsic Pontine Glioma
10/23
12/23
NCT00957086: Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Active, not recruiting
3
710
RoW
Nimotuzumab, Placebo
National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore, Innogene Kalbiotech Pte. Ltd
Carcinoma, Squamous Cell of Head and Neck
01/25
01/25
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Recruiting
3
384
RoW
Nimotuzumab, Cisplatin
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
02/24
02/24
NOTABLE-308, NCT06343116: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not yet recruiting
3
420
NA
Nimotuzumab injection, Taixinsheng, Placebo, Trifluridine/tipiracil
Biotech Pharmaceutical Co., Ltd.
Refractory Metastatic Colorectal Cancer
04/27
04/27
NCT06333821: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruiting
3
460
NA
Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab, placebo
Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
04/30
04/30
NCT06561763: TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting
3
416
NA
Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
Sun Yat-sen University
High Risk Locally Advanced Nasopharyngeal Carcinoma
08/28
08/31
NCT05772208: Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting
3
459
RoW
Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT
Fudan University
Nasopharyngeal Carcinoma
01/25
01/28
ChiCTR2400084464: Pancreatectomy with combined targeted therapy and neoadjuvant chemotherapy in locally advanced pancreatic cancer

Recruiting
3
20
 
Ninituzumab + Gemcitabine plus albumin-bound purpurinol+Radical resection
West China Hospital , Sichuan University; West China Hospital , Sichuan University, Biotech Pharmaceuticals Co., Ltd
Pancreatic Ductal Adenocarcinoma
 
 
NCT06026878: GNT Induction Treatment in Locally Advanced NPC

Recruiting
3
228
RoW
gemcitabine,nimotuzumab, toripalimab, GNT, gemcitabine, cisplatin, GP
Air Force Military Medical University, China
Nasopharyngeal Carcinoma
09/25
09/27
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting
3
2000
RoW
Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer
12/25
12/25
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting
3
2000
RoW
Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect
12/25
12/25
NOTABLE-307, NCT05978050: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting
3
354
RoW
nimotuzumab plus paclitaxel, Combined with chemotherapy, placebo plus paclitaxel, chemotherapy alone
Biotech Pharmaceutical Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
03/26
IST-Nim-PC 45, NCT06409429: Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Not yet recruiting
2/3
146
RoW
Nimotuzumab, h-R3, GX, Placebo
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
05/27
05/27
ACTRN12610000560099: A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
88
 
YM BioSciences Inc., YM BioSciences Inc.
Non-Small Cell Lung Cancer with brain metastases
 
 
ACTRN12610000571077: A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination with External Radiotherapy in Stage IIB, III and IV Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
128
 
YM BioSciences Inc., YM BioSciences Inc.
Non-Small Cell Lung Cancer (NSCLC)
 
 
ChiCTR-ONC-12002130: Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma

Completed
2
39
 
cisplatin+5-Fu+nimotuzumab
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sponsored by Biotech Pharmaceuticals Co.Ltd.
Metastatic Nasopharyngeal Carcinoma
 
 
ChiCTR-IIR-16007712: Nimotuzumab (Taixinsheng) combined with radiotherapy and chemotherapy for protecting the laryngeal function of locally advanced hypopharyngeal and laryngeal cancer patients: a multi-center, single-blind, randomized, controlled, phase II study

Recruiting
2
100
 
nimotuzumab (200mg) combine with Radiotherapy and Cisplatin ;nimotuzumab (200mg) combine with Radiotherapy and Docetaxel
People's Liberation Army General Hospital; People's Liberation Army General Hospital, biotech pharmaceutical co.,ltd
Hypopharyngeal cancer, laryngeal cancer
 
 
GASTO 1010, NCT02428764: Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Withdrawn
2
37
RoW
Nimotuzumab, Gemcitabine, Gemzar, Carboplatin, CBP, Surgery
Sun Yat-sen University
Lung Cancer
10/25
10/27
ChiCTR-OIC-16008201: Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy follow by cisplatin synchronous intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: a multicenter, prospective phase II study

Recruiting
2
60
 
Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy
The fourth affiliated hospital of Guangxi Medical University; The fourth affiliated hospital of Guangxi Medical University, Key specialist funds
Locally advanced nasopharyngeal carcinoma
 
 
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recruiting
2
67
RoW
Nimotuzumab, Radiation
Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital
Recurrent Nasopharyngeal Carcinoma
04/20
11/22
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Recruiting
2
47
RoW
Nimotuzumab, Taixinsheng, VMAT
Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
05/20
05/22
NCT03708822: Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
2
48
RoW
Docetaxel and Cisplatin and Nimotuzumab
Sun Yat-sen University
Nasopharyngeal Carcinoma
07/22
06/24
CC11, NCT06771596: Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Active, not recruiting
2
43
RoW
Nimotuzumab Injection, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Uterine Cervical Neoplasms
07/25
09/25
NCT04136600: EGFR Monoclonal Antibody for Advanced Gastric Cancer

Recruiting
2
100
RoW
EGFR antibody and Chemotherapy, Chemotherapy
Shanghai Changzheng Hospital
Gastric Cancer, Cetuximab, Nimotuzumab
08/21
12/21
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Completed
2
55
RoW
Radiotherapy, Nimotuzumab, S-1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm
12/22
06/23
Carpp-1, NCT04882462: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Not yet recruiting
2
100
NA
Nimotuzumab, Sintilimab, Chemotherapy drug
The First Affiliated Hospital of Soochow University, Biotech Pharmaceutical Co., Ltd., Cinda Biopharmaceutical (Suzhou) Co., Ltd.
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
11/21
12/22
NCT04367909: A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Recruiting
2
68
RoW
Nimotuzumab, Docetaxel, Carboplatin
Xin-Hua Xu
Oral Squamous Cell Carcinoma
12/21
12/22
NCT04833205: Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Recruiting
2
30
RoW
Nimotuzumab, EGFR-TKI
Hui Bu
Leptomeningeal Metastasis, Lung Cancer
04/22
04/23
NCT06404840: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Recruiting
2
30
RoW
nimotuzumab, AG chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
03/25
05/26
DIPG, NCT03620032: Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

Active, not recruiting
2
54
Europe
Nimotuzumab, humanized therapeutic monoclonal antibody, Vinorelbine, Chemotherapy, Radiotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University of Roma La Sapienza, Johannes Gutenberg University Mainz, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Wuerzburg University Hospital
Diffuse Intrinsic Pontine Glioma
11/22
11/24
NCT04223024: Concurrent Chemoradiotherapy with Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Active, not recruiting
2
246
RoW
CCRT+Nimotuzumab, Nimotuzumab, CCRT alone
Sun Yat-sen University
Nasopharyngeal Carcinoma
08/24
12/26
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
45
RoW
Nimotuzumab + SHR-1210
The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
12/22
09/23
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
NCT06455072: Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Recruiting
2
37
RoW
Nituzumab, monoclonal antibody, Serplulimab, Immune checkpoint inhibitors
Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province
Cervical Cancer
01/25
01/25
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Recruiting
2
53
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Recruiting
2
55
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
IST-Nim-ESCC-18, NCT06718205: Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
112
RoW
Nimotuzumab, Sintilimab, Paclitaxel-albumin, Cisplatin
The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer
09/25
09/25
NCT06405685: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Recruiting
2
30
RoW
Nimotuzumab, h-R3, AG
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
10/25
10/25
ChiCTR2000035678: Concurrent nimotuzumab with intensity modulated radiotherapy for locoregionally advanced aged nasopharyngeal carcinoma

Not yet recruiting
2
95
 
Concurrent nimotuzumab with intensity modulated radiotherapy
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, none
nasopharyngeal carcinoma
 
 
ChiCTR2100049181: Nimotuzumab plus chemotherapy for unresectable locally advanced or metastatic pancreatic cancer and biliary tract cancer: an open-label, prospective, phase II basket trial

Not yet recruiting
2
16
 
None
Peking University International Hospital; Peking University International Hospital, self-funded
pancreatic cancer and biliary tract cancer
 
 
NCT06413017: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Recruiting
2
30
RoW
Nimotuzumab, h-R3, ICIs(Immune checkpoint inhibitors), PD-1 or PD-L1
Tianjin Medical University Cancer Institute and Hospital
HCC
07/25
12/25
NCT05508347: Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Recruiting
2
170
RoW
Nituzumab/placebo, Nituzumab injection (taixinsheng)
Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Carcinoma
10/25
10/27
NCT06389760: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Recruiting
2
57
RoW
Nimotuzumab, Taixinsheng, mFOLFIRINOX, GX
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Cancer
09/26
09/26
GCR-05, NCT05606263: Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer

Recruiting
2
55
RoW
Caldonirimab and Nimotuzumab
Health Science Center of Xi'an Jiaotong University
Cervical Cancer
11/23
11/25
NCT04664244: Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Recruiting
2
43
RoW
Combination of nimotuzumab and radiotherapy
Lei Li
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab, Objective Response Rate, Progression-free Survival, Overall Survival
12/23
12/23
ChiCTR2100041780: Nimotuzumab combined with PD-1 Sintilizumab in the second-line treatment of advanced esophageal squamous cell carcinoma: a single-arm, open phase II clinical study

Recruiting
2
42
 
Nimotuzumab combined with sintilizumab
The Sixth Medical Center of PLA General Hospital; The Sixth Medical Center of PLA General Hospital, BIOTECH PHARMA
Esophageal Carcioma
 
 
ChiCTR2100051133: A single-center, single-arm, phase II clinical study of the efficacy and safety of nimotuzumab combined with sintilimab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma

Not yet recruiting
2
41
 
Nimotuzumab combined with Sintilimab
The Fifth Affiliated Hospital of Guangzhou Medical University; The Fifth Affiliated Hospital of Guangzhou Medical University, Enterprise subsidy
squamous cell carcinoma of the head and neck
 
 
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
22
RoW
Anti-PD1 antibody, nimotuzumab and capecitabine
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
02/26
08/26
NCT06988956: Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting
2
95
RoW
Nimotuzumab, Nim, Tegafur, S-1, radiotherapy
The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma
04/27
04/27
ChiCTR2200058765: A Phase II study of the safety and efficacy of sintilimab in combination with chemotherapy and Nimotuzumab induction therapy, Nimotuzumab synchronous radiotherapy (IMRT), followed by six months of maintenance therapy with sintilimab in advanced nasopharyngeal carcinoma

Recruiting
2
30
 
sintilimab combined nimotuzumab
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Innovent Biological Inc (Suzhou)
nasopharyngeal carcinoma
 
 
NCT06429904: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Active, not recruiting
2
31
RoW
Nimotuzumab+ NALIRIFOX
Peking Union Medical College Hospital
Locally Advanced Pancreatic Cancer
05/27
05/27
NCT06414577: Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Active, not recruiting
2
38
RoW
Irinotecan Liposomal combined With Nituzumab
XIANG YANQUN
Nasopharyngeal Cancer
03/25
03/25
ChiCTR2200060564: Nimotuzumab combined with neoadjuvant chemotherapy (TPF) in the treatment of resectable locally advanced head and neck squamous cell carcinoma

Not yet recruiting
2
55
 
Nimotuzumab combined with chemotherapy (PF protocol)
Xijing Hospital of the Air Force Military Medical University; Xijing Hospital of the Air Force Military Medical University, Enterprise funding
Head and neck squamous cell carcinoma
 
 
NCT05351762: Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Not yet recruiting
2
55
NA
Nimotuzumab Combined With Neoadjuvant Chemotherapy, Albumin Paclitaxel, Nedaplatin, Teggio
Xijing Hospital
Head and Neck Squamous Cell Carcinoma
05/24
07/24
Nim-PC-28, NCT06422156: SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Not yet recruiting
2
73
NA
Stereotactic body radiation, SBRT, Nimotuzumab, h-R3, mono-chemotherapy, chemotherapy
Peking University Third Hospital, Biotech Pharmaceutical Co., Ltd.
Advanced Pancreatic Cancer
06/26
06/26
NCT06490341: GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

Not yet recruiting
2
20
NA
GP Regimen, Nimotuzumab, Sintilimab, no other invention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Nasopharyngeal Carcinoma
07/26
07/27
NCT06509009: Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
2
30
NA
Nimotuzumab, no other invention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma by AJCC V8 Stage
05/26
05/27
NCT05803915: Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Not yet recruiting
2
57
RoW
Toripalimab, JS001
Peking Union Medical College Hospital
Oral Squamous Cell Carcinoma
09/24
03/26
ChiCTR2100043937: A single-arm, open phase II clinical study to evaluate the efficacy and safety of Nimotuzumab Injection combined with concurrent chemoradiotherapy in elderly patients with locally advanced inoperable esophageal squamous cell carcinoma

Recruiting
2
23
 
Nimotuzumab, Tegafur Gimer and radiotherapy
Affiliated Hospital of Nantong University; Level of the institution：, None
esophageal squamous carcinoma
 
 
NCT06039891: Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Not yet recruiting
2
55
NA
Nimotuzumab、Tislelizumab, Nimotuzumab, Tislelizumab plus radiotherapy
Peking Union Medical College Hospital
Cervical Cancer
10/24
10/27
NCT06676722: SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

Recruiting
2
20
RoW
SBRT combined with Nimotuzumab followed by Tislelizumab
The First Affiliated Hospital of Xiamen University
Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
12/26
12/27
NCT06722911: Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Recruiting
2
57
RoW
Nimotuzumab, AG
Zhejiang Provincial People's Hospital
Pancreatic Cancer Resectable
09/28
09/28
NOTABLE-309, NCT06781086: Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting
2
156
RoW
Nimotuzumab, AG regimen, Placebo
Biotech Pharmaceutical Co., Ltd., Peking University Cancer Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer, Adult
12/28
12/28
NCT06770452: HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Not yet recruiting
2
32
RoW
HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel
Zhejiang University
Metastatic Pancreatic Carcinoma
02/27
02/28
ChiCTR2300068872: Clinical study of rre-combined nimouzumab for reversing drug resistance in hepatocellular carcinoma after failure of treatment of 1-L lenalutinib-containing regimen

Recruiting
2
37
 
nimotuzumab，400mg，D1,8,15,28d/cycle
The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Hospital), Self-financing
hepatocelluar carcinoma
 
 
NCT06938503: AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Not yet recruiting
2
48
NA
AG regimen, Nimotuzumab
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Adult
04/28
04/28
NCT05316480: Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Not yet recruiting
2
42
RoW
Nimotuzumab
Fudan University
Pancreatic Neuroendocrine Neoplasm
04/25
12/26
NCT06912711: TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Not yet recruiting
2
70
RoW
Toripalimab, Nimotuzumab, surgery
Sun Yat-sen University
Nasopharyngeal Carcinoma
04/29
04/29
ChiCTR2000034375: TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Not yet recruiting
2
29
 
TIP (paclitaxel + ifosfamide + cisplatin)+Nimotuzumab+Triprilimab
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Self-financing
Penile Caner
 
 
NCT06048913: Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

Completed
2
56
RoW
Nimotuzumab, taixinsheng, S-1, chemotherapy, Concurrent radiation therapy, Chemoradiotherapy
The First Affiliated Hospital with Nanjing Medical University
Esophageal Carcinoma
01/25
01/25
NCT05024019: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Not yet recruiting
2
95
RoW
Nimotuzumab
Eye & ENT Hospital of Fudan University
Head and Neck Squamous Cell Carcinoma
08/25
08/25
NCT05355168: Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Completed
2
35
RoW
neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
Anhui Provincial Hospital
Toxicity, Drug
12/23
03/24
ChiCTR2100054151: Clinical study of neoadjuvant chemoradiation combined with Nimotuzumab and Camrelizumab in the treatment of resectable/potentially resectable locally advanced esophageal cancer

Not yet recruiting
2
57
 
Camrelizumab + Nimotuzumab + Carboplatin + Albumin Paclitaxel + radiotherapy + surgery
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Jiangsu Hengrui Pharmaceutical Co., Ltd.; Baitai Biological Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma
 
 
ChiCTR2000041139: An open-label, single-arm phase II clinical study of nimotuzumab concurrently with induction chemotherapy and sequential nimotuzumab combined with radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Recruiting
2
76
 
Nimotuzumab plus induction chemotherapy,sequential nimotuzumab plus radiotherapy or nimotuzumab combined with concurrent chemoradiotherapy
The second affiliated hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, Self-financing
Nasopharyngeal carcinoma
 
 
ChiCTR2200064587: Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy in patients with advanced head and neck cancer: A phase II singel arm trial

Not yet recruiting
2
48
 
Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy
Xijing Hospital; Xijing Hospital, clinical trials project of the air force medical university
head neck cancer
 
 
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study

Recruiting
2
26
China
The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1,000 mg/m2), Cisplatin, intravenous infusion, day 1 (80 mg/m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650 mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study.
Dongguan People's Hospital; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd.
nasopharyngeal carcinoma
 
 
ChiCTR2300072843: Prospective study of nituzumab combined with gemcitabine and albumin paclitaxel in first-line treatment of advanced pancreatic cancer

Recruiting
2
31
 
nituzumab combined with gemcitabine and albumin paclitaxel
Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Own in-hospital support
pancreatic cancer
 
 
ChiCTR2400084660: A prospective, single arm study of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer

Not yet recruiting
2
31
 
1. Nimotuzumab: Dosage:*400 mg, administered intravenously once a week (QW); or 1600 mg divided into three doses, administered intravenously on days 1, 8, and 15 (600 mg + 600 mg + 400 mg), with a 28-day treatment cycle. Preparation:Dissolve 8 vials (400 mg) of nimotuzumab injection in 250 ml of normal saline, or dissolve 12 vials (600 mg) of nimotuzumab injection in 380 ml of normal saline. The infusion time should be at least 60 minutes.2. Chemotherapy: Regimen:NALIRIFOX Components:Liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2 administered intravenously, followed by 5-FU 2400 mg/m2 continuous infusion over 46 hours. Schedule:Administered on days 1 and 15, with a 28-day cycle.
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Biotech Pharmaceutical Co., Ltd.
pancreatic cancer
 
 
ChiCTR2200063496: A prospective, single arm, phase II study of neoadjuvant treatment of resectable head and neck tumors with nituzumab combined with epimumab

Not yet recruiting
2
51
 
Nytuzumab was combined with ipilimumab ;Nytuzumab was combined with ipilimumab
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Clinical medicine research project of Tianjin Medical University General Hospital
Head and neck squamous cell carcinoma
 
 
ChiCTR2400084470: A Single-Arm, Multi-Center, Prospective Phase II Clinical Study on the neoadjuvant Tislelizumab-Nimotuzumab-GP followed by concurrent Tislelizumab-Nimotuzumab-IMRT and maintenance Tislelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma at High Risk

Recruiting
2
31
 
Neoadjuvant Tislelizumab-Nivolumab-GP followed by concurrent Tislelizumab-Nivolumab-IMRT and maintenance Tislelizumab
Fujian Cancer Hospital; Fujian Cancer Hospital, none
Locally Advanced Nasopharyngeal Carcinoma
 
 
ChiCTR2500099125: A phase II clinical study on neoadjuvant therapy of esophageal squamous cell carcinoma with tislelizumab combined with nimotuzumab and chemotherapy

Not yet recruiting
2
40
 
Tislelizumab injection Nimotuzumab injection paclitaxel for injection (albumin-bound) Cisplatin injection
Shanxi Cancer Hospital; Shanxi Cancer Hospital, self-funding
esophageal squamous cell carcinoma
 
 
ChiCTR2200057917: Phase II clinical study of nituzumab combined with first-line chemotherapy in the treatment of advanced esophageal squamous cell carcinom

Not yet recruiting
2
60
 
Nituzumab combined with chemotherapy
Cancer Hospital Affiliated to Harbin Medical University; Cancer Hospital Affiliated to Harbin Medical University, enterprise sponsor
esophagus cancer
 
 
ChiCTR2500103027: A prospective phase II study of stratified treatment of initially resectable locally advanced HNSCC based on pathological response after neoadjuvant chemo-immunotherapy

Recruiting
2
30
 
Patientsreceived tislelizumab chemotherapy for 2-3 cycles for neoadjuvant treatment . Patients who achieved MPR after surgery received tislelizumab; patients who did not achieve MPR received standard adjuvant radiotherapy combined with nimotuzumab, followed by tislelizumab.
The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, The First Affiliated Hospital of China Medical University
Head and neck squamous cell carcinoma
 
 
ChiCTR2500101420: A single-arm, single-center, open, prospective phase II clinical study of camrelizumab combined with nimotuzumab and first-line chemoradiotherapy for the treatment of recurrent and metastatic cervical cancer

Not yet recruiting
2
42
 
Camrelizumab + Nimotuzumab + CCRT
Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital, None
Recurrent and metastatic cervical cancer
 
 
 

Download Options